Marianne Ivey, PharmD, Receives International Honor in 2011
The Board of Pharmaceutical Practice of the International Pharmaceutical Federation (FIP) has named Marianne Ivey, PharmD, the 2011 recipient of the FIP Distinguished Practice Award.
FIP is the international pharmacy organization for educational institutions.
"The organization provides opportunities for pharmacists worldwide to share best practices in all segments of the pharmacy profession including inpatient and outpatient care, manufacturing, drug information, research and education. I very much appreciate FIPs recognition, "says Ivey, an associate professor of pharmacy practices and administration in the James L. Winkle College of Pharmacy.
This award is made to an individual or group who has made an outstanding contribution to Pharmaceutical Practice and is awarded every two years (in the odd years) at an annual FIP congress.
Ivey will be presented the award at the 71st FIP World Congress of Pharmacy and Pharmeceutical Sciences Sept. 2-8 in Hyderabad, India.
Tags
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.